Theramex Announces an Agreement with Enzene Biosciences Limited for the Development and Commercialisation of Tocilizumab, a Biosimilar for the Treatment of Rheumatoid Arthritis
Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has entered into an agreement with Enzene Biosciences Limited to develop, register and commercialise a biosimilar drug of Roche’s reference medicine RoActemra® (Tocilizumab). Tocilizumab, in combination with Methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis. It is planned to be commercialised from 2026 in Europe, the UK, Switzerland, and Australia.
Theramex’s Tocilizumab product will be available in parenteral vials, subcutaneous prefilled syringes and autoinjectors. The reference product RoActemra® is indicated for the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with methotrexate; moderate to severe RA adult patients who have not responded well/intolerant to DMARDs or Anti-TNFs; active systemic juvenile idiopathic arthritis in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids; juvenile idiopathic polyarthritis in patients 2 years of age and older unresponsive to MTX; treatment of Giant Cell Arteritis in adults; and chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.
Rheumatoid arthritis is a chronic condition that causes pain, swelling and stiffness in the joints. The condition usually affects the hands, feet and wrists. There may be periods where symptoms become worse, known as flares. A flare can be difficult to predict, but with treatment it's possible to decrease the number of flares and minimise or prevent long-term damage to the joints. Some people with rheumatoid arthritis also experience problems in other parts of the body, or more general symptoms such as tiredness and weight loss1.
“Rheumatoid arthritis affects more women than men, so the addition of this biosimilar drug to our existing Rheumatology portfolio continues our strategic determination to improve access and affordability of important treatments for women. We are excited to expand our focus in Rheumatology to now include rheumatoid arthritis to help even more patients with bone diseases and joint pain”, said Theramex CEO Robert Stewart .
Dr. Himanshu Gadgil, Enzene's Whole Time Director said, "The development of Enzene’s Tocilizumab, through our innovative efforts in the manufacturing of monoclonal antibodies, marks another highlight in a series of endeavours driven by our mission to provide affordable and expanded access to crucial medicines. Our partnership with Theramex bolsters our mission to bring affordable healthcare to patients across the world”.
About Theramex
Theramex is a leading global speciality pharmaceutical company dedicated to women and their health. We support women at every stage of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis. Our commitment is to listen to and understand our patients, serve their needs and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through every stage of life.
About Enzene Biosciences Ltd.
Enzene is an innovation-driven biotech company, a subsidiary of Alkem Laboratories Ltd. (One of the top five pharmaceutical companies in India*) located in Pune, India. Enzene's focus lies in producing biosimilars, novel biologics, synthetic peptides and phytopharmaceuticals. Enzene also offers a range of biologics CDMO and CMO services.
(*as per the latest IQVIA data of MAT July 2021)
For more information on Enzene Biosciences Ltd., please visit www.enzene.com
For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com
1 https://www.nhs.uk/conditions/rheumatoid-arthritis/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211223005258/en/
Contact information
Theramex
Jesús López | Associate Director, Communication & Digital | Jesus.Lopez@Theramex.com
Enzene Biosciences Ltd.
For media enquiries,
Dr. Tarun Chawla
Head - Business Development & Business Operations
Enzene Biosciences Ltd.
For any further enquiries, please reach out to: bd@enzene.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
‘BLUE LOCK - TOKYO EGOIST -’ kicks off on Saturday, November 2225.11.2025 15:07:00 EET | Press release
In its efforts to promote nighttime tourism, the Tokyo Metropolitan Government is developing new attractions that illuminate the capital after dark. As part of this initiative, projection mapping is being presented year-round on the iconic Tokyo Metropolitan Government Building No. 1, transforming its façade into a canvas of light and sound. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251121922505/en/ ©Muneyuki Kaneshiro, Yusuke Nomura, KODANSHA/BLUE LOCK Production Committee. A brand-new production inspired by the internationally popular soccer anime“BLUE LOCK”, titled BLUE LOCK – TOKYO EGOIST –, began screening on Saturday, November 22. On the first day of the screening, a mini-event was held at the Tokyo Metropolitan Government Plaza, where voice actors Kazuki Ura (voice of Yoichi Isagi) and Hiroshi Kamiya (voice of Jinpachi Ego) joined fans in celebrating the premiere. Scenes from the Opening Day of the New Production
Henderson Municipal Power & Light builds multigigabit FTTH network with Adtran fiber access technology25.11.2025 15:00:00 EET | Press release
Adtran today announced that Henderson Municipal Power & Light (HMP&L) is expanding broadband services across Henderson, Kentucky, using its open, intelligent fiber access platform. The highly scalable network leverages Adtran’s AI-powered insights to boost performance and reliability, enabling HMP&L to deliver fast, dependable multigigabit fiber-to-the-home (FTTH) services to residents and businesses. Fully integrated with Mosaic One and GLDS BroadHub® platforms, the solution simplifies network management and elevates the customer experience. The strong partnership between Adtran and HMP&L is enhancing access to digital resources, providing support to local businesses and driving regional economic growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125416908/en/ Adtran’s fiber access technology is helping HMP&L drive multigigabit connectivity to homes and businesses throughout Henderson. “We’re committed to providing t
How Banks and Fintech Will Verify in 2026: Regula Study25.11.2025 15:00:00 EET | Press release
Regula’s report, “What’s Reshaping IDV in Banking & Fintech: 2026 Trends and Predictions,” reveals that biometric verification has become the most attacked point in the digital identity verification (IDV) process across financial organizations. New global data shows that at least three in ten financial institutions are hit by impersonation fraud, driving a shift toward more robust identity verification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125171096/en/ Survey data from Regula shows banks and fintechs align on automation and integration challenges, but diverge sharply on user-experience concerns. According to survey data from organizations in the US, UAE, Germany, and Singapore, at least three in ten banks and fintechs report biometric verification as the stage most frequently targeted by fraudsters—ahead of document checks or other onboarding steps. Many of these incidents involve AI-generated media, including
Infineon and HTEC Showcase Humanoid Robotic Head at Infineon’s OktoberTech™ Silicon Valley 2025 Show25.11.2025 15:00:00 EET | Press release
The long-standing collaboration between Infineon Technologies AG and HTEC reached a new milestone this October at OktoberTech™ Silicon Valley 2025, where the two companies presented their jointly developed 360° Awareness Humanoid Robotic Head. The technology, which is a result of close partnership in embedded engineering, sensor fusion, and AI integration, captured the attention of attendees and was honored with the event’s Partner Innovation Award. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125008456/en/ The Humanoid Robotic Head, developed by HTEC using Infineon technologies, won the Partner Innovation Award at Infineon's OktoberTech event for its innovative 360° multi-sensory awareness and human-interactive robotic capabilities. The Robotic Head represents a major step toward more perceptive and responsive machines. It demonstrates how cutting-edge sensing and processing technologies can enable robots to understand
SS&C Expands European Wealth Management Capabilities with New MiFID License in Ireland25.11.2025 14:00:00 EET | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced significant expansion of its European wealth management business with the establishment of SS&C Wealth Services Europe Ltd. The business has been granted authorization under the Markets in Financial Instruments Directive (MiFID) by the Central Bank of Ireland. The license strengthens SS&C’s ability to serve the European Union’s wealth management sector. The company can now deliver its full suite of technology-enabled wealth management solutions directly from Ireland. The new operation builds on SS&C’s successful U.K. wealth management business, creating a pan-European platform with advanced technology, deep regulatory expertise, and comprehensive servicing capabilities. Based in Dublin, the business will focus on helping financial institutions modernize and scale their wealth operations through SS&C’s integrated wealth platform, custody, and back-office services. SS&C employs more than 550 professionals in Ireland, servici
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom